AUS Edition 
NZ Edition 
UK Edition 
CA Edition 
USA Edition 
FRA Edition 
GER Edition 
ESP Edition 
ITA Edition 
NLD Edition 
PRT Edition 
SWE Edition 
GRC Edition 
IND Edition 
POL Edition 
BRA Edition 
ZAF Edition 
RUS Edition 
CHN Edition 
UAE Edition 
⚠
✓
NewAmsterdam Pharma Company N.V. Ordinary Shares (NASDAQ:NAMS)
20.5 USD
-0.530 2.520%Sponsored Reports
Loading...
| Previous Close (in USD) | 21.03 |
|---|---|
| Change | -0.530 2.520% |
| 52 W H/L (in USD) | 26.350/5.633 |
| EBITDA (in USD) | -198.541M |
| PE Ratio | -- |
| Volume | 169511 |
| Diluted Eps TTM | -2.78 |
| Total Assets (in USD) | 347.097M |
|---|---|
| Total Liabilities (in USD) | 58.704M |
| Revenue TTM (in USD) | 6.862M |
| Cash (in USD) | 340.45M |
| Market Cap (in USD) | 1,746.624 M |
| Revenue Per Share TTM | 0.082 |
| Gross Profit TTM (in USD) | -- |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
Employees: 40
Key Executives
| Sr. No. | Name | Title | Year Born |
|---|---|---|---|
| 1. | Dr. Michael Harvey Davidson FACC, Facc., Facp., M.D. | CEO, Pres, Exec. Board Member & Director | 1957 |
| 2. | Dr. Johannes Jacob Pieter Kastelein FESC, M.D., Ph.D. | Founder, Chief Scientific Officer & Member of Exec. Board | 1954 |
| 3. | Ms. Louise Kooij | CFO, Treasurer, Member of Exec. Board & Director | NA |
| 4. | Mr. Douglas F. Kling | COO, VP & Director | 1973 |
| 5. | Mr. Jim Jacobson | Chief Legal Officer & Sec. | NA |
| 6. | Ms. Lina Gugucheva | Chief Bus. Officer | NA |
| 7. | Dr. Sheng Cui Ph.D. | VP & Head of Chemistry Manufacturing and Controls (CMC) | NA |
| 8. | Ms. Annie Neild | VP & Head of Regulatory Affairs | NA |
| 9. | Dr. Michael Harvey Davidson FACC, Facp., M.D. | CEO, President, Executive Board Member & Director | 1956 |
| 10. | Dr. Johannes Jacob Pieter Kastelein FESC, M.D., Ph.D. | Founder, Chief Scientific Officer, Member of Executive Board & Director | 1954 |
Peers
Sector: Healthcare
Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
|
NVO
Novo Nordisk A/S |
-0.560 0.691% | 81.41 | 41.580 | 31.153 | 2.134 | 32.989 | 2.113 | 4.700 |
|
NONOF
Novo Nordisk A/S |
-0.410 0.506% | 80 | 41.060 | 31.250 | 2.078 | 33.111 | 2.113 | 4.700 |
|
VRTX
Vertex Pharmaceuticals Inc |
-1.290 0.280% | 455.39 | 29.670 | 24.331 | 10.385 | 5.832 | 9.334 | 20.004 |
|
REGN
Regeneron Pharmaceuticals Inc |
+2.820 0.540% | 518.25 | 29.070 | 20.121 | 7.570 | 3.823 | 6.950 | 19.423 |
Income Statement
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 |
|---|---|---|---|
| Income Before Tax | -78.052M | -28.599M | -5.749M |
| Minority Interest | - | - | - |
| Net Income | -148.884M | -28.815M | -6.093M |
| Selling General Administrative | 18.144M | 3.944M | 1.372M |
| Gross Profit | 97.5M | - | - |
| Reconciled Depreciation | 0.072M | 0.014M | 0.001M |
| Ebit | -67.56M | -29.826M | -5.429M |
| Ebitda | -6.877M | -29.812M | -5.428M |
| Depreciation And Amortization | 60.683M | 0.014M | 0.001M |
| Operating Income | -67.56M | -29.826M | -5.429M |
| Other Operating Expenses | 104.46M | 29.835M | 5.429M |
| Interest Expense | 0.271M | 0.216M | 0.344M |
| Tax Provision | 0M | 0M | 0M |
| Interest Income | 0.011M | 0.009M | 0M |
| Net Interest Income | -0.26M | -0.207M | -0.344M |
| Income Tax Expense | 70.832M | 0.216M | 0.344M |
| Total Revenue | 97.5M | 0M | 0M |
| Total Operating Expenses | 104.46M | 29.835M | 5.429M |
| Cost Of Revenue | - | - | - |
| Total Other Income Expense Net | -10.492M | 1.227M | -0.32M |
| Net Income From Continuing Ops | -78.052M | -28.599M | -5.749M |
| Net Income Applicable To Common Shares | - | -28.599M | -5.749M |
Balance Sheet
(Currency in USD)| Breakdown | 31-12-2023 | 31-12-2022 | 31-12-2021 | 31-12-2020 |
|---|---|---|---|---|
| Total Assets | 347.097M | 531.583M | 59.782M | 9.231M |
| Intangible Assets | 0.17M | - | - | - |
| Other Current Assets | 6.341M | - | 1.492M | 1.358M |
| Total Liab | 58.704M | 47.062M | 9.991M | 12.808M |
| Total Stockholder Equity | 288.393M | 484.521M | 49.791M | -3.577M |
| Other Current Liab | 23.972M | 11.278M | 0.001M | 0.762M |
| Common Stock | 10.173M | 599.191M | 83.876M | 2.5M |
| Capital Stock | 10.173M | 599.191M | 83.876M | 2.5M |
| Retained Earnings | -316.973M | -119.361M | -34.676M | -6.077M |
| Good Will | - | - | - | - |
| Other Assets | - | - | 0.718M | - |
| Cash | 340.45M | 438.522M | 53.092M | 7.861M |
| Cash And Equivalents | - | - | - | - |
| Total Current Liabilities | 49.897M | 35.461M | 9.88M | 12.808M |
| Current Deferred Revenue | 8.942M | 13.008M | 3.607M | - |
| Net Debt | -340.39M | -438.404M | -52.928M | 3.789M |
| Short Term Debt | 0.06M | 0.062M | 0.053M | 11.65M |
| Short Long Term Debt | - | - | - | 11.65M |
| Short Long Term Debt Total | 0.06M | 0.118M | 0.164M | 11.65M |
| Other Stockholder Equity | 273.798M | - | 0.591M | - |
| Property Plant Equipment | - | - | 0.19M | 0.012M |
| Total Current Assets | 346.791M | 448.133M | 58.874M | 9.219M |
| Long Term Investments | - | - | - | - |
| Short Term Investments | - | - | - | - |
| Net Receivables | 1.881M | 1.941M | 4.29M | - |
| Long Term Debt | - | - | - | - |
| Inventory | -1.881M | - | - | - |
| Accounts Payable | 16.923M | 11.113M | 6.219M | 0.396M |
| Accumulated Other Comprehensive Income | 4.422M | 4.691M | 0.591M | - |
| Non Currrent Assets Other | 0.035M | 0.146M | 0.718M | - |
| Non Current Assets Total | 0.306M | 83.45M | 0.908M | 0.012M |
| Capital Lease Obligations | 0.06M | 0.118M | 0.164M | 0M |
| Long Term Debt Total | - | - | - | - |
Cash Flow
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 |
|---|---|---|---|
| Investments | 0.715M | -0.02M | -0.013M |
| Total Cashflows From Investing Activities | - | -0.02M | -0.013M |
| Total Cash From Financing Activities | 375.177M | 68.99M | 11.32M |
| Net Income | -78.052M | -28.599M | -5.749M |
| Change In Cash | 385.43M | 45.231M | 5.361M |
| Begin Period Cash Flow | 53.092M | 7.861M | 2.5M |
| End Period Cash Flow | 438.522M | 53.092M | 7.861M |
| Total Cash From Operating Activities | 7.972M | -25.164M | -5.97M |
| Depreciation | 0.072M | 0.014M | 0.001M |
| Other Cashflows From Investing Activities | - | - | - |
| Dividends Paid | - | - | - |
| Change To Inventory | - | - | - |
| Sale Purchase Of Stock | - | - | - |
| Other Cashflows From Financing Activities | -2.534M | -0.02M | -0.013M |
| Capital Expenditures | 0.013M | 0.02M | 0.013M |
| Change In Working Capital | 11.462M | 3.822M | -0.528M |
| Other Non Cash Items | 70.568M | -0.007M | 0.306M |
| Free Cash Flow | 7.959M | -25.184M | -5.983M |
Funds
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Polar Capital Biotech S Inc | 1 year ago | 1250000 |
| 2. | PGIM Jennison Health Sciences Z | 1 year ago | 489125 |
| 3. | Jennison Health Sciences Equity | 1 year ago | 489125 |
| 4. | Fidelity Select Pharmaceuticals Port | 1 year ago | 243700 |
| 5. | UTM IM GBP AXA Framlington Biotech | 1 year ago | 238976 |
| 6. | APO Medical Opportunities R | 1 year ago | 165127 |
| 7. | Arctic Aurora LifeScience I USD | 1 year ago | 127796 |
| 8. | Eastern Shore Small Cap Equity | 1 year ago | 108355 |
| 9. | iA Thematic Innovation SRP75100 | 1 year ago | 105830 |
| 10. | ArrowMark Small Cap Gro | 1 year ago | 91232 |
| 11. | Meridian Small Cap Growth Legacy | 1 year ago | 91232 |
| 12. | Empower Small Cap Growth/TimesSquare SP | 1 year ago | 76385 |
| 13. | Fidelity Nasdaq Composite Index | 1 year ago | 52185 |
| 14. | HealthInvest Sustainable Healthcare E | 1 year ago | 43494 |
| 15. | Vanguard International Explorer Inv | 1 year ago | 40308 |
| 16. | GuideStone Funds Small Cap Equity Instl | 1 year ago | 27000 |
| 17. | Nationwide International Sm Cp R6 | 1 year ago | 23400 |
| 18. | RIM Global Bioscience EUR | 1 year ago | 23097 |
| 19. | AMG TimesSquare Small Cap Growth Z | 1 year ago | 19570 |
| 20. | LUX IM Global Medtech HX | 1 year ago | 18830 |
Institutions
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | FCPM III SERVICES BV | 1 year ago | 11831461 |
| 2. | Bain Capital Life Sciences Investors, LLC | 1 year ago | 10473913 |
| 3. | Viking Global Investors LP | 1 year ago | 8024565 |
| 4. | RA Capital Management, LLC | 1 year ago | 7864000 |
| 5. | Medicxi Ventures Management (Jersey) Ltd | 1 year ago | 2869565 |
| 6. | Goldman Sachs Group Inc | 1 year ago | 2768642 |
| 7. | Adage Capital Partners Gp LLC | 1 year ago | 1824601 |
| 8. | Millennium Management LLC | 1 year ago | 947527 |
| 9. | GMT Capital Corp | 1 year ago | 943136 |
| 10. | Jennison Associates LLC | 1 year ago | 930851 |
| 11. | HHG PLC | 1 year ago | 636231 |
| 12. | Avidity Partners Management LP | 1 year ago | 475000 |
| 13. | Octagon Capital Advisors LP | 1 year ago | 408000 |
| 14. | Eversept Partners, LLC | 1 year ago | 374404 |
| 15. | Parkman Healthcare Partners LLC | 1 year ago | 300750 |
| 16. | ArrowMark Colorado Holdings, LLC (ArrowMark Partners) | 1 year ago | 296807 |
| 17. | AXA SA | 1 year ago | 276328 |
| 18. | Opaleye Management Inc | 1 year ago | 265388 |
| 19. | TimesSquare Capital Management, LLC | 1 year ago | 228616 |
| 20. | Ensign Peak Advisors Inc | 1 year ago | 191956 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
Sponsored Articles
Loading...
Related Articles
Loading...